Rheumatoid arthritis and lymphatic cancer

Macfarlane, Gary J.; Rj, Black

doi:10.1016/0959-8049(96)00242-0

Cited by 16 publications

(10 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with rheumatoid arthritis have been reported to have a two‐ to threefold increased risk of lymphatic cancer (eg, non‐Hodgkin's and Hodgkin's lymphoma) 3 , 4 . The suggestion that disease‐modifying drugs further increase this risk is controversial, as it is difficult to match patients for disease severity.…”

Section: Discussionmentioning

confidence: 99%

“…Patients with rheumatoid arthritis have been reported to have a two-to threefold increased risk of lymphatic cancer (eg, non-Hodgkin's and Hodgkin's lymphoma). 3,4 The suggestion that diseasemodifying drugs further increase this risk is controversial, as it is difficult to match patients for disease severity. Disease activity may, in itself, be a risk factor for development of lymphoma, 5 and, because more potent immunosuppressive agents are used in more severe disease, there may not be a true relationship between treatments and lymphoma.…”

Section: Clinical Recordmentioning

confidence: 99%

“…Cyclosporin has been implicated in the development of lymphoma, predominantly in association with transplantation 1 , 2 . In addition, there are an increasing number of reports of B‐cell lymphomas in rheumatoid arthritis patients that would seem to implicate methotrexate 3 . ‐ 10 …”

mentioning

confidence: 99%

“…1,2 In addition, there are an increasing number of reports of B-cell lymphomas in rheumatoid arthritis patients that would seem to implicate methotrexate. [3][4][5][6][7][8][9][10]…”

mentioning

confidence: 99%

See 3 more Smart Citations

Remission of lymphoma after drug withdrawal in rheumatoid arthritis

Lim

Bertouch

2002

Medical Journal of Australia

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Clinical Recordmentioning

confidence: 99%

mentioning

confidence: 99%

“…1,2 In addition, there are an increasing number of reports of B-cell lymphomas in rheumatoid arthritis patients that would seem to implicate methotrexate. [3][4][5][6][7][8][9][10]…”

mentioning

confidence: 99%

See 2 more Smart Citations

Remission of lymphoma after drug withdrawal in rheumatoid arthritis

Lim

Bertouch

2002

Medical Journal of Australia

View full text Add to dashboard Cite

“…The first is activity of RA. According to several reports RA patients show a two-or three-fold higher incidence of malignant lymphoma than normal controls (13)(14)(15). Despite administration of oral prednisolone and MTX, his systemic arthritis could not be adequately controlled, and the titer of RAHA suddenly increased together with the appearance of multiple rheumatoid nodules and phlebitis, suggesting that immune mechanisms, including B cells, were highly activated in this patient.…”

Section: Discussionmentioning

confidence: 99%

Malignant Lymphoma Associated with Rheumatoid Arthritis, Developing Shortly after Initiation of Oral Methotrexate

et al. 2004

View full text Add to dashboard Cite

We report a patient with rheumatoid arthritis (RA) who developed malignant lymphoma of the diffuse large B-cell type in the right submandibular region shortly after initiation of oral methotrexate (MTX). Despite cessation of MTX, the lymphadenopathy did not regress, and only reached complete remission after 3 courses of CHOP therapy followed by irradiation. In this patient highly active RA itself was considered to be the main cause of malignant lymphoma, and MTX might have contributed to the development by modifying the immune system. When RA is highly active, MTX should be used carefully because of the possible development of malignant lymphoma as well as other serious complications. (Internal Medicine 43: 135-138, 2004)

show abstract

Risk of malignancy among patients with rheumatic conditions

et al. 2000

View full text Add to dashboard Cite

Previous studies have described an increased risk of malignancy in subjects diagnosed with rheumatic conditions, most notably rheumatoid arthritis (RA). Our aim was to quantify and compare risks for site‐specific malignancy among hospitalized patients with RA, osteoarthritis (OA) and other rheumatic conditions in a nationwide, population‐based cohort. Subjects were identified from Scottish hospital in‐patient records from 1981 to 1996 and followed up by computer linkage of the Scottish Cancer Registry and the national registry of deaths. Expected cancer incidence was calculated from national cancer rates and related to the observed incidence by the standardized incidence ratio (SIR). Among RA patients, there was an increased risk for hematopoietic [males SIR= 2.13, 95% confidence interval (CI) 1.7–2.7; females SIR = 1.76, 95% CI 1.5–2.1], lung (males SIR = 1.32, 95% CI 1.2–1.5; females SIR = 1.44, 95% CI 1.3–1.6) and prostate (SIR = 1.26, 95% CI 1.0–1.6) cancers. Reduced risk were seen for colorectal cancer (males SIR = 0.87, 95% CI 0.7–1.1; females SIR = 0.71, 95% CI 0.6–0.9) and, among females, stomach cancer (SIR = 0.70, 95% CI 0.5–1.0). The excess risk for hematopoietic cancer and the reduced risk for colorectal and stomach cancers were sustained over 10 years of follow‐up. An overall decreased risk of cancer was observed for patients with OA; the greatest reductions were observed for colorectal (males SIR = 0.88, 95% CI 0.8–1.0; females SIR = 0.84, 95% CI 0.8–0.9), stomach (males SIR = 0.79, 95% CI 0.7–0.9; females SIR = 0.66, 95% CI 0.6–0.8) and lung (males SIR = 0.72, 95% CI 0.7–0.8; females SIR = 0.84, 95% CI 0.8–0.9) malignancies, with decreased risks generally still evident at 10 years of follow‐up. Our results support several previous findings regarding the incidence of hematopoietic and colorectal malignancies in RA patients. In addition, we have shown a large decrease in stomach cancer among patients with OA and females with RA that warrants further investigation since it may provide clues to possible prevention strategies. To further our knowledge about the underlying mechanisms of altered risk in cancer patients with rheumatic conditions, population studies requiring primary data collection are required. Int. J. Cancer 88:497–502, 2000. © 2000 Wiley‐Liss, Inc.

show abstract

Rheumatoid arthritis and lymphatic cancer

Cited by 16 publications

References 15 publications

Remission of lymphoma after drug withdrawal in rheumatoid arthritis

Remission of lymphoma after drug withdrawal in rheumatoid arthritis

Malignant Lymphoma Associated with Rheumatoid Arthritis, Developing Shortly after Initiation of Oral Methotrexate

Risk of malignancy among patients with rheumatic conditions

Contact Info

Product

Resources

About